Secondary analysis of 2260 patients with resected stage III colon cancer in a phase III adjuvant FOLFOX trial: postoperative ctDNA positivity (20.4%) was associated with shorter disease-free survival (HR 5.03; 5-year DFS 27.7% vs 77.1%) and overall survival (HR 4.45).
Secondary analysisn = 2,260
Sinicrope et al. Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147)